CXCR4 and prostate carcinoma: Plerixafor (AMD3100), a CXCR4 antagonist approved by the FDA, was shown in a subcutaneous xenograft mouse model of human prostate carcinoma to dissociate the prostate cancer cells from their sanctuary site (the BM) and thus sensitize them to chemotherapy treatment (124).